TuHURA Biosciences opened lower at $1.51, compared with its previous close of $1.52. In the last trading session, the stock traded between $1.37 and $1.57. It showed a downward intraday trend.
An investment of $100 made 3 years ago in TuHURA Biosciences is now worth
$ 22.84
Resulting in a loss of
$ 77.16 (77.16%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.08 (-5.33%)
Day High
$1.57
Day Low
$1.37
Day Open
$1.51
Prev Close
$1.52
Volume
6,46,221
1W Return
-15.95%
1M Return
-24.06%
3M Return
-37.57%
6M Return
-40.04%
1Y Return
-39.54%
Market Cap ($ Mn)
92
PE Ratio
-
PB Ratio
7.37
PEG Ratio
-
ROE
-187.32%
ROCE
-179.74%
EPS (TTM)
-
1 Week
-15.95%
1 Month
-24.06%
3 Months
-37.57%
6 Months
-40.04%
9 Months
11.55%
TuHURA Biosciences secures US patent for TBS-2025 antibody therapy
USPTO issued Patent No. 12,760,104 for TuHURA Biosciences' TBS-2025. Patent covers anti-VISTA antibodies, including bispecific and multispecific variants. Protection extends to combinations with PD-1 inhibitors, chemotherapy, and radiotherapy. Patent term runs until February 18, 2042, excluding potential extensions. Scope includes treatments for autoimmune diseases and infections beyond cancer.
1mo agoTuHURA Biosciences secures US patent for DOR antagonist cancer therapies
TuHURA Biosciences received U.S. Patent No. 12,734,168 from the USPTO. The patent covers DOR antagonists targeting Myeloid Derived Suppressor Cells. Therapy aims to reprogram immunosuppressive microenvironments in cancer. Includes rights for DOR antagonist combination therapies against metastasis.
1mo agoTuHURA Biosciences secures FDA IND clearance for TBS-2025 AML study
FDA granted IND clearance for TBS-2025, a VISTA-inhibiting antibody for AML. Phase 1b study targets relapsed/refractory mutNPM1 AML patients failing menin inhibitors. Trial will assess safety and efficacy before moving to dose-optimization stage. Preclinical murine models showed TBS-2025 improved survival comparable to chemotherapy. Company also advancing IFx-2.0 in Phase 3 trial for Merkel Cell Carcinoma.
1mo agoTuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY
TuHURA Biosciences delivered a Q2 EPS of $(0.14), beating the $(0.15) estimate by 6.67%. The result marks a 33.33% YoY improvement in losses compared to $(0.21) per share in the previous year, signaling narrowing deficits.
3mo agoTuHURA Biosciences CEO to present at Canaccord Genuity conference
TuHURA Biosciences announced that President and CEO James A. Bianco will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 12, 2026. The presentation is scheduled for 12:30pm ET, and an archived webcast will be available on the company's website. TuHURA is a Phase 3 immuno-oncology company developing therapeutics to overcome resistance to cancer immunotherapy.
3mo agoTuHURA Biosciences files IND for TBS-2025 AML trial
TuHURA Biosciences has submitted an IND to the FDA for its TBS-2025 VISTA antibody to treat specific AML subsets. The filing incorporates FDA guidance from a previous IND in February 2026. The company focuses on overcoming immunotherapy resistance in cancer treatment.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in TuHURA Biosciences is now worth
$ 22.84
Resulting in a loss of
$ 77.16 (77.16%)
Note: Past profits do not guarantee future returns.
